ClinicalTrials.Veeva

Menu
U

University of Malaya Medical Centre | Department of Rheumatology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 685509
Vincristine
6-Mercaptopurine
Methotrexate
Prednisolone
Empagliflozin
Cytarabine
Pembrolizumab
Odevixibat
Cyclophosphamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 56 total trials

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Active, not recruiting
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This...

Active, not recruiting
Head and Neck Squamous Cell Carcinoma (HNSCC)
Drug: Cetuximab
Drug: Ezabenlimab

D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of...

Active, not recruiting
HIV Infections
Drug: Darunavir
Drug: NRTIs

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling
Kidney Disease, Chronic
Drug: Placebo matching BI 690517
Drug: Empagliflozin

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with...

Active, not recruiting
Biliary Atresia
Drug: Odevixibat
Drug: Placebo

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection...

Enrolling
SARS-CoV-2 Infection
Drug: Azvudine
Drug: Placebo
Locations recently updated

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis
Drug: Survodutide
Drug: Placebo matching survodutide

Objectives:Primary: To demonstrate the safety of allogeneic UC-MSCs administered by injection for complex perianal fistulas in patients with Crohn's...

Enrolling
Fistula in Ano
Perianal Fistula Due to Crohn's Disease
Biological: PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells

This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exa...

Begins enrollment in 1 month
Bronchiectasis
Drug: Placebo matching BI 1291583
Drug: BI 1291583

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling
Chronic Kidney Diseases
Dialysis-dependent Kidney Failure
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Other: Placebo

Trial sponsors

U
Boehringer Ingelheim logo
Population Health Research Institute (PHRI) logo
Boston Scientific logo
N
C
K
Abbott logo
A
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems